EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

被引:1048
作者
Peters, M. J. L. [1 ]
Symmons, D. P. M. [2 ]
McCarey, D. [3 ]
Dijkmans, B. A. C. [1 ,4 ]
Nicola, P. [5 ]
Kvien, T. K. [6 ]
McInnes, I. B. [7 ]
Haentzschel, H. [8 ]
Gonzalez-Gay, M. A. [9 ]
Provan, S. [6 ]
Semb, A. [6 ]
Sidiropoulos, P. [10 ]
Kitas, G. [11 ]
Smulders, Y. M. [12 ]
Soubrier, M. [13 ]
Szekanecz, Z. [14 ]
Sattar, N. [15 ]
Nurmohamed, M. T. [1 ,4 ,13 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Rheumatol, NL-1007 MB Amsterdam, Netherlands
[2] Univ Manchester, Manchester, Lancs, England
[3] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland
[4] Jan van Breemen Inst, Dept Rheumatol, Amsterdam, Netherlands
[5] Fac Med Lisbon, Dept Prevent Med, Lisbon, Portugal
[6] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[7] Univ Glasgow, Ctr Rheumat Dis, Glasgow G12 8QQ, Lanark, Scotland
[8] Univ Klinikum Leipzig, Rheumazentrum, Leipzig, Germany
[9] Hosp Xeral Calde, Lugo, Spain
[10] Univ Crete, Sch Med, Dept Rheumatol Clin Immunol & Allergy, Iraklion, Greece
[11] Hosp NHS Trust Russells Hall Hosp, Dudley Grp, Dudley, England
[12] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, NL-1007 MB Amsterdam, Netherlands
[13] Hop Gabriel Montpied, Serv Rhumatol, Clermont Ferrand, France
[14] Univ Debrecen, Dept Rheumatol, Debrecen, Hungary
[15] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
关键词
CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; CONVERTING ENZYME-INHIBITION; POPULATION-BASED COHORT; LONG-TERM; LIPID PROFILES; ANKYLOSING-SPONDYLITIS; MYOCARDIAL-INFARCTION; PSORIATIC-ARTHRITIS; PLASMA HOMOCYSTEINE;
D O I
10.1136/ard.2009.113696
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Methods: A multidisciplinary expert committee was convened as a task force of the EULAR Standing Committee for Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists and epidemiologists, representing nine European countries. Problem areas and related keywords for systematic literature research were identified. A systematic literature research was performed using MedLine, Embase and the Cochrane library through to May 2008. Based on this literature review and in accordance with the EULAR's "standardised operating procedures'', the multidisciplinary steering committee formulated evidence-based and expert opinion-based recommendations for CV risk screening and management in patients with inflammatory arthritis. Results: Annual CV risk assessment using national guidelines is recommended for all patients with RA and should be considered for all patients with AS and PsA. Any CV risk factors identified should be managed according to local guidelines. If no local guidelines are available, CV risk management should be carried out according to the SCORE function. In addition to appropriate CV risk management, aggressive suppression of the inflammatory process is recommended to further lower the CV risk. Conclusions: Ten recommendations were made for CV risk management in patients with RA, AS and PsA. The strength of the recommendations differed between RA on the one hand, and AS and PsA, on the other, as evidence for an increased CV risk is most compelling for RA.
引用
收藏
页码:325 / 331
页数:7
相关论文
共 103 条
[1]  
Aubry MC, 2007, J RHEUMATOL, V34, P937
[2]   Risk of Cardiovascular Mortality in Patients With Rheumatoid Arthritis: A Meta-Analysis of Observational Studies [J].
Avina-Zubieta, J. Antonio ;
Choi, Hyon K. ;
Sadatsafavi, Mohsen ;
Etminan, Mahyar ;
Esdaile, John M. ;
Lacaille, Diane .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (12) :1690-1697
[3]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[4]   Glucocorticoids in the treatment of early and late RA [J].
Bijlsma, JWJ ;
Boers, M ;
Saag, KG ;
Furst, DE .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (11) :1033-1037
[5]  
Björnådal L, 2002, J RHEUMATOL, V29, P906
[6]   Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis [J].
Boers, M ;
Nurmohamed, MT ;
Doelman, CJA ;
Lard, LR ;
Verhoeven, AC ;
Voskuyl, AE ;
Huizinga, TWJ ;
van de Stadt, RJ ;
Dijkmans, BAC ;
van der Linden, S .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :842-845
[7]   Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs [J].
Bolten, WW .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (01) :7-13
[8]  
BUDMENDOZA C, 2003, LUPUS, V12, P607
[9]   All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists [J].
Carmona, Loreto ;
Descalzo, Miguel Angel ;
Perez-Pampin, Eva ;
Ruiz-Montesinos, Dolores ;
Erra, Alba ;
Cobo, Tatiana ;
Gomez-Reino, Juan J. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :880-885
[10]   INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].
CASTELLI, WP ;
GARRISON, RJ ;
WILSON, PWF ;
ABBOTT, RD ;
KALOUSDIAN, S ;
KANNEL, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838